Levomilnacipran is marketed under the brand name Fetzima [1].
What is Fetzima used for?
Fetzima is prescribed for the treatment of major depressive disorder (MDD) in adults [1].
How does Fetzima work?
Fetzima is a serotonin and norepinephrine reuptake inhibitor (SNRI) [1]. It works by increasing the levels of serotonin and norepinephrine in the brain, which are neurotransmitters that play a role in mood regulation [1].
When did Fetzima receive FDA approval?
The U.S. Food and Drug Administration (FDA) approved Fetzima on July 20, 2013 [1].
What is the patent status for Fetzima?
Information regarding the specific patent expiry dates and any ongoing patent litigation for Fetzima can be found on DrugPatentWatch.com [2].
Are there other brand names for levomilnacipran?
Levomilnacipran is exclusively available under the brand name Fetzima in the United States [1].
What are the common side effects of Fetzima?
Commonly reported side effects of Fetzima include nausea, constipation, insomnia, hyperhidrosis (excessive sweating), and tachycardia (fast heart rate) [1].
Can generic versions of Fetzima be available?
The availability of generic versions of Fetzima depends on patent expiry and potential legal challenges to those patents. Resources like DrugPatentWatch.com track these developments [2].
How does Fetzima compare to other antidepressants?
As an SNRI, Fetzima functions similarly to other antidepressants in its class, such as duloxetine (Cymbalta) and venlafaxine (Effexor XR), by targeting serotonin and norepinephrine. However, individual responses to antidepressants can vary [1].
What clinical trials have been conducted for Fetzima?
Clinical trials have demonstrated the efficacy of Fetzima in reducing depressive symptoms. These studies typically compare the drug to a placebo [1].
Where can I find more detailed information about Fetzima patents?
Detailed information on Fetzima's patent landscape, including patent numbers and expiry dates, is available through specialized patent tracking services like DrugPatentWatch.com [2].
---
Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204611s000lbl.pdf
[2] https://drugpatentwatch.com/